Esperion Therapeutics Patent Case Against Renata Reassigned

Esperion Therapeutics sued Renata Limited in a case docketed as 24-cv-06017. The court issued two orders on April 20, 2026, including a case reassignment. No judge is currently listed as assigned.

The underlying dispute has not yet been detailed in available filings. Esperion is a pharmaceutical company known for its cholesterol-lowering drug bempedoic acid (marketed as Nexletol). Renata Limited is a generic drug manufacturer based in Bangladesh.

The case number and party identities suggest this is a Hatch-Waxman patent dispute — a generic manufacturer files an Abbreviated New Drug Application, the brand-name holder sues within 45 days to trigger a 30-month stay on FDA approval, and the parties litigate patent validity and infringement in federal court.

The reassignment order is the only docket activity on record. Reassignments happen for several reasons: a judge recuses, a related case already sits with another judge, or the court's random assignment draws a correction. None of those reasons have been stated publicly.

Until a judge accepts the assignment and the docket fills in, the procedural posture is essentially a blank slate.

The filing date is listed as unknown, but the docket number — 24-cv-06017 — places the original filing in 2024. That means the case has been pending for over a year with minimal public docket activity. In Hatch-Waxman litigation, early months are often consumed by service, scheduling orders, and claim construction prep, so thin early dockets are not unusual.

What matters is whether the 30-month stay clock is running and when it expires, because that date drives settlement pressure harder than any motion practice.